Biogen Reports Strong Q2 Revenue Growth, Drives Stock Performance
On July 30, 2026, Biogen (NASDAQ: BIIB) saw its stock rise nearly 2% as investors reacted positively to the company's second-quarter results. Despite a decline in adjusted net income due to higher expenses and interest costs from recent acquisitions like Apellis Pharmaceuticals, revenue grew by 3% year-over-year to $2.7 billion — exceeding analyst expectations of $2.4 billion. The growth was primarily driven by Biogen’s portfolio of newer medicines, which saw a significant increase in sales with $1.06 billion generated and a 24% annual rise. The company also revised its full-year revenue guidance upward to mid-single-digit growth from an earlier forecasted decline. Although it lowered adjusted earnings per share (EPS) guidance due to ongoing financial pressures, the market responded favorably as investors recognized progress in Biogen’s strategic shift. The stock outperformed broader markets like the S&P 500 and signaled confidence that its pivot toward growth-focused therapies is working.
Topics: biotech guidance update revenue growth stock performance